Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Example of details involved in acquisition talks: like ONCY

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Oct 12, 2023 6:19am

107 Views

Post# 35680025

RE:RE:RE:RE:RE:RE:RE:RE:RE:Example of details involved in acquisition talks: like ONCY

Most or all of the Esmo and Asco prsentations never had positive impacts on the SP. I remember one a couple year ago when the SP was close to 5$ CAD, a slow decline of the SP followed and look where we stand! We need a clear sign of BP interest (NR) or wonerfull results well appreciated by the markets. Fingers crossed! GL

<< Previous

Bullboard Posts

Next >>

Apolo IV Acquisition and Marviken Ontario sign merger agreement